Aspire Biopharma Holdings Statistics
Aspire Biopharma Holdings (ASBP) Stock Statistics & Valuation Metrics
Total Valuation
Aspire Biopharma Holdings has a market cap or net worth of $11.64M. The enterprise value is -$4.62T.
- Market Cap
- $11.64M
- Enterprise Value
- -$4.62T
Share Statistics
Aspire Biopharma Holdings has 1,402,557 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,402,557
- Owned by Insiders
- ―
- Owned by Institutions
- 4.39%
Financial Efficiency
Aspire Biopharma Holdings’s return on equity (ROE) is 3.84 and return on invested capital (ROIC) is 395.26%.
- Return on Equity (ROE)
- 3.84
- Return on Assets (ROA)
- -18.66
- Return on Invested Capital (ROIC)
- 395.26%
- Return on Capital Employed (ROCE)
- 3.08
- Revenue Per Employee
- 3,101
- Profits Per Employee
- -12.24M
- Employee Count
- 2
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.02
Valuation Ratios
The current PE Ratio of Aspire Biopharma Holdings is -1.00. Aspire Biopharma Holdings’s PEG ratio is -0.01.
- PE Ratio
- -1.00
- PS Ratio
- 9.44
- PB Ratio
- 0.71
- Price to FCF
- -0.13
- Price to Operating Cash Flow
- -1.15
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Aspire Biopharma Holdings had revenue of 6,202 and earned -24.48M in profits. Earnings per share was -16.38.
- Revenue
- 6,202
- Gross Profit
- -116
- Operating Income
- -19.35M
- Pretax Income
- -24.48M
- Net Income
- -24.48M
- EBITDA
- -11.33M
- Earnings Per Share (EPS)
- -16.38
Cash Flow
In the last 12 months, operating cash flow was -7.19M and capital expenditures 0, giving a free cash flow of -7.19M billion.
- Operating Cash Flow
- -7.19M
- Free Cash Flow
- -7.19M
- Free Cash Flow per Share
- -6.92
Dividends & Yields
Aspire Biopharma Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -776.17%
- Earnings Yield
- -132.67%
Stock Price Statistics
- Beta
- 1.81
- 52-Week Price Change
- -92.42%
- 50-Day Moving Average
- 8.41
- 200-Day Moving Average
- 14.08
- Relative Strength Index (RSI)
- 50.62
- Average Volume (3m)
- 30.09K
Financial Position
Aspire Biopharma Holdings as a current ratio of 0.17, with Debt / Equity ratio of -21.72%
- Current Ratio
- 0.17
- Quick Ratio
- 0.14
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -0.03
- Interest Coverage Ratio
- -2.27
Taxes
In the past 12 months, Aspire Biopharma Holdings has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Aspire Biopharma Holdings EV to EBITDA ratio is -3.42, with an EV/FCF ratio of 1.56.
- EV to Sales
- -115.11
- EV to EBITDA
- -3.42
- EV to Free Cash Flow
- 1.56
- EV to Operating Cash Flow
- 1.56
Balance Sheet
Aspire Biopharma Holdings has $12.17M in cash and marketable securities with $0.00 in debt, giving a net cash position of $12.17M billion.
- Cash & Marketable Securities
- $12.17M
- Total Debt
- $0.00
- Net Cash
- $12.17M
- Net Cash Per Share
- $8.67
- Tangible Book Value Per Share
- $11.33
Margins
Gross margin is 18.35%, with operating margin of -7259.92%, and net profit margin of -11314.24%.
- Gross Margin
- 18.35%
- Operating Margin
- -7259.92%
- Pretax Margin
- -11314.24%
- Net Profit Margin
- -11314.24%
- EBITDA Margin
- 3367.37%
- EBIT Margin
- -6466.27%
Analyst Forecast
The average price target for Aspire Biopharma Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 94.71%

